Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers

American society of clinical oncology clinical practice guideline

Dawn L. Hershman, Christina Lacchetti, Robert H. Dworkin, Ellen M. Lavoie Smith, Jonathan Bleeker, Guido Cavaletti, Cynthia Chauhan, Patrick Gavin, Antoinette Lavino, Maryam B. Lustberg, Judith Paice, Bryan Schneider, Mary Lou Smith, Tom Smith, Shelby Terstriep, Nina Wagner-Johnston, Kate Bak, Charles L. Loprinzi

Research output: Contribution to journalArticle

434 Citations (Scopus)

Abstract

Purpose: To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Methods: A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and severity of neuropathy as measured by neurophysiologic changes, patient-reported outcomes, and quality of life. Results: A total of 48 RCTs met eligibility criteria and comprise the evidentiary basis for the recommendations. Trials tended to be small and heterogeneous, many with insufficient sample sizes to detect clinically important differences in outcomes. Primary outcomes varied across the trials, and in most cases, studies were not directly comparable because of different outcomes, measurements, and instruments used at different time points. The strength of the recommendations is based on the quality, amount, and consistency of the evidence and the balance between benefits and harms. Recommendations: On the basis of the paucity of high-quality, consistent evidence, there are no agents recommended for the prevention of CIPN. With regard to the treatment of existing CIPN, the best available data support a moderate recommendation for treatment with duloxetine. Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPN treatment options. Further research on these agents is warranted.

Original languageEnglish
Pages (from-to)1941-1967
Number of pages27
JournalJournal of Clinical Oncology
Volume32
Issue number18
DOIs
StatePublished - Jun 20 2014

Fingerprint

Medical Oncology
Peripheral Nervous System Diseases
Practice Guidelines
Survivors
Drug Therapy
Randomized Controlled Trials
Nortriptyline
Therapeutics
Baclofen
Amitriptyline
Tricyclic Antidepressive Agents
Ketamine
Neuralgia
Sample Size
Gels
Quality of Life
Incidence
Research
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers : American society of clinical oncology clinical practice guideline. / Hershman, Dawn L.; Lacchetti, Christina; Dworkin, Robert H.; Lavoie Smith, Ellen M.; Bleeker, Jonathan; Cavaletti, Guido; Chauhan, Cynthia; Gavin, Patrick; Lavino, Antoinette; Lustberg, Maryam B.; Paice, Judith; Schneider, Bryan; Smith, Mary Lou; Smith, Tom; Terstriep, Shelby; Wagner-Johnston, Nina; Bak, Kate; Loprinzi, Charles L.

In: Journal of Clinical Oncology, Vol. 32, No. 18, 20.06.2014, p. 1941-1967.

Research output: Contribution to journalArticle

Hershman, DL, Lacchetti, C, Dworkin, RH, Lavoie Smith, EM, Bleeker, J, Cavaletti, G, Chauhan, C, Gavin, P, Lavino, A, Lustberg, MB, Paice, J, Schneider, B, Smith, ML, Smith, T, Terstriep, S, Wagner-Johnston, N, Bak, K & Loprinzi, CL 2014, 'Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline', Journal of Clinical Oncology, vol. 32, no. 18, pp. 1941-1967. https://doi.org/10.1200/JCO.2013.54.0914
Hershman, Dawn L. ; Lacchetti, Christina ; Dworkin, Robert H. ; Lavoie Smith, Ellen M. ; Bleeker, Jonathan ; Cavaletti, Guido ; Chauhan, Cynthia ; Gavin, Patrick ; Lavino, Antoinette ; Lustberg, Maryam B. ; Paice, Judith ; Schneider, Bryan ; Smith, Mary Lou ; Smith, Tom ; Terstriep, Shelby ; Wagner-Johnston, Nina ; Bak, Kate ; Loprinzi, Charles L. / Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers : American society of clinical oncology clinical practice guideline. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 18. pp. 1941-1967.
@article{f8c2fe37f75a4169ae501f4b14f20320,
title = "Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline",
abstract = "Purpose: To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Methods: A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and severity of neuropathy as measured by neurophysiologic changes, patient-reported outcomes, and quality of life. Results: A total of 48 RCTs met eligibility criteria and comprise the evidentiary basis for the recommendations. Trials tended to be small and heterogeneous, many with insufficient sample sizes to detect clinically important differences in outcomes. Primary outcomes varied across the trials, and in most cases, studies were not directly comparable because of different outcomes, measurements, and instruments used at different time points. The strength of the recommendations is based on the quality, amount, and consistency of the evidence and the balance between benefits and harms. Recommendations: On the basis of the paucity of high-quality, consistent evidence, there are no agents recommended for the prevention of CIPN. With regard to the treatment of existing CIPN, the best available data support a moderate recommendation for treatment with duloxetine. Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPN treatment options. Further research on these agents is warranted.",
author = "Hershman, {Dawn L.} and Christina Lacchetti and Dworkin, {Robert H.} and {Lavoie Smith}, {Ellen M.} and Jonathan Bleeker and Guido Cavaletti and Cynthia Chauhan and Patrick Gavin and Antoinette Lavino and Lustberg, {Maryam B.} and Judith Paice and Bryan Schneider and Smith, {Mary Lou} and Tom Smith and Shelby Terstriep and Nina Wagner-Johnston and Kate Bak and Loprinzi, {Charles L.}",
year = "2014",
month = "6",
day = "20",
doi = "10.1200/JCO.2013.54.0914",
language = "English",
volume = "32",
pages = "1941--1967",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers

T2 - American society of clinical oncology clinical practice guideline

AU - Hershman, Dawn L.

AU - Lacchetti, Christina

AU - Dworkin, Robert H.

AU - Lavoie Smith, Ellen M.

AU - Bleeker, Jonathan

AU - Cavaletti, Guido

AU - Chauhan, Cynthia

AU - Gavin, Patrick

AU - Lavino, Antoinette

AU - Lustberg, Maryam B.

AU - Paice, Judith

AU - Schneider, Bryan

AU - Smith, Mary Lou

AU - Smith, Tom

AU - Terstriep, Shelby

AU - Wagner-Johnston, Nina

AU - Bak, Kate

AU - Loprinzi, Charles L.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Purpose: To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Methods: A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and severity of neuropathy as measured by neurophysiologic changes, patient-reported outcomes, and quality of life. Results: A total of 48 RCTs met eligibility criteria and comprise the evidentiary basis for the recommendations. Trials tended to be small and heterogeneous, many with insufficient sample sizes to detect clinically important differences in outcomes. Primary outcomes varied across the trials, and in most cases, studies were not directly comparable because of different outcomes, measurements, and instruments used at different time points. The strength of the recommendations is based on the quality, amount, and consistency of the evidence and the balance between benefits and harms. Recommendations: On the basis of the paucity of high-quality, consistent evidence, there are no agents recommended for the prevention of CIPN. With regard to the treatment of existing CIPN, the best available data support a moderate recommendation for treatment with duloxetine. Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPN treatment options. Further research on these agents is warranted.

AB - Purpose: To provide evidence-based guidance on the optimum prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) in adult cancer survivors. Methods: A systematic literature search identified relevant, randomized controlled trials (RCTs) for the treatment of CIPN. Primary outcomes included incidence and severity of neuropathy as measured by neurophysiologic changes, patient-reported outcomes, and quality of life. Results: A total of 48 RCTs met eligibility criteria and comprise the evidentiary basis for the recommendations. Trials tended to be small and heterogeneous, many with insufficient sample sizes to detect clinically important differences in outcomes. Primary outcomes varied across the trials, and in most cases, studies were not directly comparable because of different outcomes, measurements, and instruments used at different time points. The strength of the recommendations is based on the quality, amount, and consistency of the evidence and the balance between benefits and harms. Recommendations: On the basis of the paucity of high-quality, consistent evidence, there are no agents recommended for the prevention of CIPN. With regard to the treatment of existing CIPN, the best available data support a moderate recommendation for treatment with duloxetine. Although the CIPN trials are inconclusive regarding tricyclic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing baclofen, amitriptyline HCL, and ketamine, these agents may be offered on the basis of data supporting their utility in other neuropathic pain conditions given the limited other CIPN treatment options. Further research on these agents is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84905454673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905454673&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.54.0914

DO - 10.1200/JCO.2013.54.0914

M3 - Article

VL - 32

SP - 1941

EP - 1967

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -